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of the steroid 3α-hydroxy-5αpregnane-11,20-dione (alfaxalone)
with propofol or diazepam
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,

Many GABAergic drugs are in clinical use as anesthetics, sedatives, or anxiolytics. We have investigated
the actions of the combinations of the neuroactive steroid 3α-hydroxy-5α-pregnane-11,20-dione
(alfaxalone) with the intravenous anesthetic propofol or the benzodiazepine diazepam. The goal
of the study was to determine whether coapplication of alfaxalone reduces the effective doses and
concentrations of propofol and diazepam. Behavioral effects of alfaxalone, propofol, diazepam, and
the combinations of the drugs were evaluated during a 30-min activity test in mice. Functional effects of
the individual drugs and drug combinations were tested by measuring the decay times of spontaneous
inhibitory postsynaptic currents in rat hippocampal neurons, and peak current responses from
heterologously expressed concatemeric α1β2γ2L GABAA receptors. Co-administration of alfaxalone
increased the sedative actions of propofol and diazepam in mice. The combination of alfaxalone with
propofol or diazepam increased the decay times of sIPSCs and shifted the concentration-response
relationships for GABA-activated receptors to lower transmitter concentrations. We infer that
alfaxalone acts as a co-agonist to enhance the GABAergic effects of propofol and diazepam. We propose
that co-administration of alfaxalone, and possibly other neuroactive steroids, can be employed to
reduce dosage requirements for propofol and diazepam.
The γ-aminobutyric acid type A (GABAA) receptor is the principal inhibitory ionotropic transmitter-gated ion
channel in the brain1. A number of GABAergic compounds are in clinical use as anesthetics, sedatives, anxiolytics, and/or anticonvulsants2,3. These include intravenous anesthetics, such as propofol, and benzodiazepines, such
as diazepam. Propofol is used for induction and maintenance of general anesthesia of surgical patients as well as
sedation of critically ill patients. Diazepam is first-line treatment for seizures, and is also used to treat anxiety
and panic attacks. Both drugs are widely-used clinically but can have significant shortcomings due to undesired
side effects. Propofol can cause hypotension and respiratory depression at plasma concentrations reached during
anesthesia4,5. Diazepam, particularly at higher doses, results in anterograde amnesia and sedation6,7. Thus it could
be advantageous to develop approaches to administer lower doses of the drugs while maintaining overall clinical
efficacy.
One conceivable approach to reduce drug dosage without compromising the desired clinical effects is to
combine the clinical agent with another GABAergic compound, such as a potentiating neuroactive steroid, that
acts as a background agonist or a co-agonist in activating the GABAA receptor. A recent study showed that the
neurosteroid 3α-hydroxy-5α-pregnan-20-one (allopregnanolone) augments the ability of propofol to reduce
action potential firing and prolong inhibitory postsynaptic currents in neocortical neurons8. We have previously
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shown that etomidate-mediated potentiation of the recombinant α1β2γ2L GABAA receptor is amplified in the
presence of the neurosteroid 3α-hydroxy-5β-pregnan-20-one (pregnanolone). The potential clinical relevance
of the effect was demonstrated in behavioral studies, which revealed left-shifted dose-response relationships for
loss-of-righting by etomidate in mice and Xenopus tadpoles, in the presence of the neurosteroid9.
To further explore this phenomenon, and to determine how it manifests in various in vivo and in vitro experimental assays, we investigated the behavioral and functional effects of co-administration of the synthetic neuroactive steroid 3α-hydroxy-5α-pregnane-11,20-dione (alfaxalone) with propofol or diazepam. We employed
alfaxalone because of its low logP value and relatively fast washout10. We show that the combination of alfaxalone
with propofol or diazepam enhances sedation in mice as assessed by quantifying lack of movement during a
30-min activity test conducted immediately following drug administration. Animals injected with the combination of propofol and alfaxalone also demonstrated loss-of-righting in the majority of animals whereas administration of either drug alone was ineffective. Coapplication of alfaxalone with propofol or diazepam increased
the decay times of spontaneous inhibitory postsynaptic currents (sIPSCs) in rat hippocampal neurons. In
two-electrode voltage clamp recordings from heterologously expressed concatemeric α1β2γ2L GABAA receptors, coapplication of alfaxalone with propofol or diazepam shifted the GABA concentration-response curves to
lower transmitter concentrations in a manner consistent with energetic additivity. Overall, the data indicate that
the GABAergic effects of propofol and diazepam can be amplified by the steroid alfaxalone.

Results

The effects of the steroid alfaxalone on propofol- or diazepam-induced sedation in mice. Time

at rest (absence of movement) was recorded during a 30-min locomotor activity test to evaluate potential sedative effects following intraperitoneal injections of alfaxalone (30 mg/kg), propofol (50 mg/kg), the combined
drug treatment (propofol + alfaxalone) or normal saline. A repeated measures (rm) ANOVA on the time at
rest data (Fig. 1A) revealed a significant drug effect, [F(3,41) = 7.27, p = 0.005) and drug × time interaction
[F(15,205) = 4.16, p < 0.00005], indicating significant differences among some of the groups, although these
differences varied across the test session. Subsequent simple main effects tests showed that the time at rest for
the mice treated with propofol + alfaxalone was significantly greater (Bonferroni corrected for 5 comparisons)
on average across post-injection time during the test session than those of the saline control [F(1,41) = 18.09,
p = 0.0005], alfaxalone alone [F(1,41) = 8.39, p = 0.030], or propofol alone [F(1,41) = 13.64, p = 0.003], groups.
Analyzing differences between groups as a function of post-injection time showed that the effect of the propofol + alfaxalone treatment on time at rest occurred fairly rapidly but was not particularly long-lasting. Specifically,
significantly increased rest times were observed in the propofol + alfaxalone treated mice by 5-min post-injection compared to levels displayed by each single drug treatment and saline control groups, and these differences
remained significantly different up until and including the 20-min time block (see Fig. 1A for “p” values associated with the pair-wise comparisons for specific 5-min time blocks within each of these three contrasts). Lastly,
our results also showed that each of the single drug-treated groups did not differ from those of the saline control
mice across the post-injection time.
A similar analysis was conducted on mice injected (ip) with diazepam alone (4 mg/kg), alfaxalone alone
(30 mg/kg), the combination of diazepam + alfaxalone, or normal saline (Fig. 1B). An rmANOVA performed on
the time at rest data revealed a significant drug effect, [F(3,36) = 55.68, p < 0.00005] and drug × time interaction
[F(15,180) = 3.24, p = 0.0004]. Simple main effects tests showed that the diazepam + alfaxalone group displayed
significantly increased rest times compared to saline control [F(1,36) = 136.12, p < 0.00005], alfaxalone alone
[F(1,36) = 113.36, p < 0.00005], or diazepam alone [F(1,36) = 54.33, p < 0.00005] treated mice on average across
the time blocks. Our analyses on group performance as a function of post-injection time indicated that the effect
of the diazepam + alfaxalone treatment on time at rest occurred fairly rapidly and was long-lasting. This was documented by increased rest times in the diazepam + alfaxalone treated mice by 5-min post-injection compared to
levels displayed by each single drug treatment and saline control groups. These differences remained significantly
greater throughout the entire 30-min test session (see Fig. 1B for specific “p” values associated with the pair-wise
comparisons for the 5-min time blocks). In addition, the diazepam alone group had significantly increased rest
times relative to the saline control mice [F(1,36) = 18.46, p = 0.0006] (Fig. 1B), with significant pair-wise comparisons being observed for the 5–25 post-injection time blocks (see Fig. 1B for the “p” values associated with these
comparisons).
To provide additional perspective concerning the magnitudes of the behavioral effects resulting from the
administration of propofol + alfaxalone or diazepam + alfaxalone, we compared the performance levels induced
by these treatments with those resulting from the mathematical sums of the respective single drug applications.
For this purpose, we computed the percent change in the mean times at rest for each of the individual and combined drug treatments by normalizing them to the mean percentages observed in the saline-injected controls
from each of the two studies. We then summed the percentages from each of the single drug treatments and
plotted them, along with percentages derived for the co-administered groups, as a function of time across the
test session. The data from the study involving the co-administration of propofol + alfaxalone (Fig. 2A) showed
that, at the beginning of the test session, the percent time at rest above baseline was approximately 7 times
higher for the co-administered group compared to that derived from adding together the percentages of the
single applications of propofol and alfaxalone. These differences declined over the session such that the percent
time at rest above baseline was slightly greater in the combined individual drug application group compared to
those of the co-administered group by the last time interval. In contrast, the data from the co-administration
of diazepam + alfaxalone study (Fig. 2B) revealed that the percent time at rest above baseline was higher in the
co-administered group compared to those observed in the summed, single drug applications throughout the test
session. The co-administered group exhibited increased percent times at rest that ranged from 8.3 times higher
during the first 5-min interval to a low of a 1.4-fold difference at 15 min. Taken together, the percent change in the
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Figure 1. Effects of combining alfaxalone with propofol, or with diazepam on mouse behavior. (A) A 30min activity test was conducted immediately following i.p. injections of normal saline (20 Units), propofol
(50 mg/kg), alfaxalone (30 mg/kg), or the combination of propofol (50 mg/kg) + alfaxalone (30 mg/kg), to
determine drug effects on time at rest (absence of movement) as a function of post-injection time (5-min
blocks) across the test session (means ± S.E.M.; n = 11–12 mice per treatment group). A repeated measures
(rm) ANOVA revealed a significant drug effect (**p = 0.0005) and drug × time interaction (***p < 0.00005),
with the propofol + alfaxalone mice exhibiting significantly increased time at rest compared to the single drug/
saline control groups on average across the test session. Significant between-groups comparisons are shown
for these contrasts: saline vs. propofol + alfaxalone at 5, 10, 15 (*p < 0.003), and 20 (*p = 0.031) min postinjection; alfaxalone vs. propofol + alfaxalone at 5, 10 (†p < 0.002), and 20 (†p = 0.038) min; and propofol vs.
propofol + alfaxalone at 5, 10 (#p < 0.0002), and 15 and 20 (#p < 0.040) min. No significant differences were
observed for the contrasts involving the saline vs. propofol or saline vs. alfaxalone groups. (B) A separate
study was conducted on an independent cohort of naïve mice to examine the potential sedating drug effects
following i.p. injections of normal saline (20 Units), diazepam (4 mg/kg), alfaxalone (30 mg/kg), or the
combination of diazepam (4 mg/kg) + alfaxalone (30 mg/kg) on time at rest (n = 10 for each group). An
rmANOVA yielded a significant drug effect (**p < 0.00005) and drug × time interaction (***p = 0.0004),
with the diazepam + alfaxalone treated mice having significantly greater times at rest compared to the saline,
alfaxalone, and diazepam groups on average across the session. Between-groups comparisons conducted
within these contrasts showed robust differences between each of the single drug/saline control groups relative
to the diazepam + alfaxalone treated mice for every post-injection time (5–30 min) interval (p < 0.0002; for
the comparisons involving saline (*), alfaxalone (†), or diazepam (#), respectively). The diazepam group also
had significantly increased rest times relative to the saline control mice, with pair-wise comparisons revealing
significant differences at 10, 15, 20, and 25-min post-injection (††p < 0.003).

time spent at rest above baseline for the co-administered drug groups supports the general idea that the sedating
effects of the drug combinations exceeded the additive effects of the sum of the individual drug applications at
least for some of the earlier post-injection time intervals.
The mice were also scored for loss-of-righting. A loss of the righting reflex was observed in 10/12 mice in the
propofol + alfaxalone group, while it was not observed in any mice (0/11) from the other three groups treated with
saline, propofol or alfaxalone. In the diazepam + alfaxalone group, loss-of-righting was observed in 2/10 mice. In
saline- or alfaxalone-treated groups no mice (0/10) exhibited loss of righting whereas 1/10 mice treated with diazepam alone demonstrated loss of the righting reflex. We note that there is some apparent discordance between
the time at rest and the loss-of-righting data across the two drug studies. In the propofol + alfaxalone study, high
levels of time at rest and loss-of-righting were both observed in the co-administered drug group. In contrast, in
the diazepam + alfaxalone study, loss-of-righting was observed in only 20% of the mice in the co-administered
drug group, although the mice in this group typically displayed high levels of time at rest throughout most of the
test session. The latter finding was due to most mice in the co-administered group exhibiting a post-injection
response of not moving for extended periods of time, although many of them did not roll over on their sides or
backs and therefore were not scored as showing a loss-of-righting.

The effects of propofol, diazepam, and alfaxalone on the decay time courses of sIPSCs. We
tested the effect of coapplication of alfaxalone with propofol or diazepam on the decay time course of sIPSCs.
Under control conditions, i.e., in the absence of GABAergic modulators, the mean 100-to-25% decay time (τD)
of sIPSCs from cultured rat hippocampal neurons was 41 ± 9 ms (mean ± S.D.; n = 17 cells). A sample averaged
sIPSC is shown in Fig. 3.
The concentrations of alfaxalone were selected based on previous data11. Exposure to 10 nM alfaxalone produced no effect (τD = 42 ± 10 ms; n = 9 cells; p > 0.9) while the application of 300 nM alfaxalone increased the
decay time to 85 ± 26 ms (n = 9; p < 0.001). Sample sIPSCs are shown in Fig. 3 and the data are summarized in
Fig. 4A.
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Figure 2. Comparison of the behavioral effects of from the co-administration of drugs with the sum of
effects of individual drugs. (A) The graph compares the performance levels induced by the co-administration
of propofol + alfaxalone to that resulting from the mathematical sums of the single drug applications. The
magnitude of change in the mean percent times at rest above baseline for the co-administration of the drugs was
greater early on in the test session, being approximately 7 times higher during the first time interval compared
to that derived from adding together the percentages of the single applications of propofol and alfaxalone. These
differences declined over the session such that the percentages from the two conditions were roughly equivalent
by the end of the test session. (B) The graph compares the performance levels induced by the co-administration
of diazepam + alfaxalone to that resulting from the mathematical sums of the single drug applications. The
percent time at rest above baseline was consistently higher throughout the test session in the co-administered
group compared to the percent change observed in the summed, single drug applications. The degree of change
in the percent times at rest above baseline ranged from being 8.3 to 1.4 times higher in the co-administered
drug group.

Bath exposure to micromolar concentrations of propofol increased τD. In the presence of 1 μM or 3 μM propofol, the mean decay times were 82 ± 22 ms (n = 7; p < 0.001) or 131 ± 7 ms (n = 4; p < 0.001), respectively. At
lower concentrations of propofol tested (10–300 nM), the effects were not significantly different from the control
value (Fig. 4B).
The propofol-induced increase of decay times was not affected by coapplication of 10 nM alfaxalone with
propofol, i.e., at any tested propofol concentration the τD was not different in the absence and presence of 10 nM
alfaxalone (Fig. 4B). In contrast, the combination of 300 nM alfaxalone with 100 nM to 1 μM propofol prolonged
the decay time beyond that observed with either drug alone. At 100 and 300 nM propofol the effects of coapplication with 300 nM alfaxalone can be described as supra-additive because exposure to propofol alone did not
prolong τD. The results are summarized in Fig. 4B.
Exposure of the cells to 10–1000 nM diazepam increased the decay times of sIPSCs. The τD was 63 ± 13 (n = 6;
p < 0.01 vs. control data), 65 ± 16 ms (n = 6; p < 0.01) or 87 ± 27 ms (n = 5; p < 0.001) with bath-applied 10, 100
or 1000 nM diazepam. The application of 1–3 nM diazepam did not have a significant effect on the decay time
course.
Coapplication of 10 nM alfaxalone did not modify diazepam-induced prolongation of τD at any tested concentration of diazepam (Fig. 4C). In the presence of the combination of 300 nM alfaxalone and 10 nM, 100 nM
or 1 μM diazepam, the decay times were greater than in the presence of either drug alone. However, alfaxalone
and diazepam alone at these concentrations had significant effects on the decay time. The calculated sums of
individual effects were greater than the control-subtracted effects of the drug combinations. For the combination of 10 nM diazepam +300 nM alfaxalone, the control-subtracted τD was 119 ± 62 ms whereas the sum of
control-subtracted effects of individual drugs was 67 ± 31 ms. Similarly, for the combinations of 100 nM or 1 μM
diazepam +300 nM alfaxalone, the control-subtracted decay times were 123 ± 37 and 123 ± 35 ms, and the sums
of individual drug effects were 69 ± 33 and 91 ± 39 ms, respectively. We used two-way ANOVA12 (but see13) to
determine if the differences between the combined treatments and the sums of individual treatments were significant. Significant interactions were found for alfaxalone and 10 nM diazepam [F(1,34) = 6.91; p < 0.013] or 100 nM
diazepam [F(1,32) = 13.67; p < 0.001]. The interaction failed to reach statistical significance for 1 μM diazepam
[F(1,31) = 4.00; p = 0.054].

The effects of alfaxalone on potentiation of recombinant concatemeric α1β2γ2L GABAA receptors by propofol and diazepam. Alfaxalone, propofol and diazepam potentiate the αβγ GABAA receptor

activated by low concentrations of the transmitter14–17. We examined the effects of the drugs, individually and in
combination, on peak responses from concatemeric α1β2γ2L GABAA receptors activated by a low concentration
of GABA. Raw current responses were converted to units of open probability, as described in Methods, that were
analyzed in the framework of the co-agonist concerted transition model18,19.
Fitting Equation (1) to pooled estimated open probability (Po) data obtained in the presence of 1–1000 μM
GABA yielded a KGABA (equilibrium dissociation constant of the closed receptor for GABA) of 35.3 ± 6.6 μM
(best-fit parameter ± standard error of the fit) and a cGABA (measure of gating efficacy for GABA; see Methods)
of 0.0045 ± 0.0004. Analysis of data from receptors activated by 10–2000 μM propofol gave a KPRO (equilibrium
ScIeNTIFIc REPOrtS | (2018) 8:10341 | DOI:10.1038/s41598-018-28754-7
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Figure 3. Effects of alfaxalone, propofol and diazepam on synaptic currents. Sample averaged sIPSCs recorded
under control conditions, or in the presence of 10 nM alfaxalone (ALF), 300 nM alfaxalone, 10 nM propofol
(PRO), 1 μM propofol, 3 nM diazepam (DZP), 1 μM diazepam, or the combinations of propofol + alfaxalone or
diazepam + alfaxalone. The drugs were added to the bath at least 10 min before recordings. All traces are from
separate cells.

dissociation constant of the closed receptor for propofol) of 44.8 ± 8.9 μM and a cPRO of 0.04 ± 0.002. The data and
the fits are shown in Fig. 5A.
Alfaxalone and diazepam exhibit low efficacy as direct activators of the GABAA receptor. This makes direct
determination of the binding and gating parameters in the wild-type receptor technically unfeasible. To determine the binding and gating properties for alfaxalone and diazepam, we measured the potentiation properties
of these two drugs coapplied with a low concentration (2 μM) of GABA. In this experiment, GABA acts as a
co-agonist that facilitates channel opening and unveils the functional effect of a weak activator.
The data showing potentiation of GABA-activated receptors by alfaxalone, diazepam, or propofol are given in
Fig. 5B. Using Equation (1), we estimate that KALF (equilibrium dissociation constant of the closed receptor for
alfaxalone) is 2.9 ± 0.5 μM and cALF is 0.11 ± 0.006. For diazepam, we estimate that KDZP (equilibrium dissociation
constant of the closed receptor for diazepam) is 0.17 ± 0.02 μM and cDZP is 0.18 ± 0.004. We also recorded potentiation of GABA-activated receptors by propofol, which yielded a KPRO of 52.8 ± 25.7 μM and a cPRO of 0.03 ± 0.01.
These values are similar to the estimates obtained from direct activation by propofol (44.8 μM and 0.04, respectively), indicating that the actions of GABA and propofol are energetically additive and independent. The data
indicate that the potentiating actions of propofol are not due to the drug modifying the affinity of the receptor to
the transmitter. Instead, propofol acts as a co-agonist, modifying the open-closed equilibrium. This finding is in
agreement with previous reports20,21. The activation properties of the receptor in the presence of GABA, propofol,
alfaxalone, and diazepam are summarized in Table 1.
The binding of GABA (to two sites) contributes −6.38 kcal/mol to stabilization of the open state, shifting the
open-closed equilibrium by 50,000-fold toward the open state. Propofol contributes −5.70 kcal/mol of stabilization energy. Alfaxalone and diazepam contribute −2.59 kcal/mol and −1.01 kcal/mol, respectively. The relatively
weak potentiating effect observed in the presence of diazepam (Fig. 5B) is, in part, due to the receptor containing
a single high-affinity binding site for diazepam.
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Figure 4. Summary of the effects of alfaxalone, propofol and diazepam on synaptic currents. (A) Summary
of the decay time courses of sIPSCs recorded under control conditions or in the presence of 10 nM or 300 nM
alfaxalone. The graph shows data from each cell tested (open circles) and mean ± S.D. for the experimental
condition (filled circles and error bars). (B) Summary of the decay time courses of sIPSCs recorded in the
presence of propofol with or without alfaxalone. The open symbols show data from each cell tested, and the
filled symbols and error bars show mean ± S.D. Due to saturation at lower propofol concentrations, 3 μM
propofol was not tested in the presence of 300 nM alfaxalone. Statistical analysis was done by comparing the
decay times for 10 nM-3 μM propofol to control, using ANOVA with Dunnett’s correction. For combinations
of propofol and alfaxalone, the top symbol applies to comparison of propofol + alfaxalone with alfaxalone
alone. The bottom symbol applies to comparison of propofol + alfaxalone with propofol alone. (C) Summary
of the decay time courses of sIPSCs recorded in the presence of diazepam with or without alfaxalone. The open
symbols show data from each cell tested, and the filled symbols and error bars show mean ± S.D. Statistical
analysis was done by comparing the decay times for 1 nM-1 μM diazepam to control. For combinations of
diazepam and alfaxalone and, the top symbol applies to comparison of diazepam + alfaxalone with alfaxalone
alone. The bottom symbol applies to comparison of diazepam + alfaxalone with diazepam alone. In (B) and
(C), the solid line shows the decay time under control conditions (no modulators). The dashed line shows the
decay time in the presence of 10 nM alfaxalone. The dotted line shows the decay time in the presence of 300 nM
alfaxalone. The number of cells was 3–17 for control, drug, or drug combinations. #not significant; *p < 0.05;
**p < 0.01; ***p < 0.001.

We next determined whether the estimated affinity and efficacy values for alfaxalone and diazepam can be
used to accurately predict shifts in GABA-activation curves in the presence of a fixed concentration of a modulator. For that, we measured GABA concentration-response relationships in the presence of 1 μM alfaxalone or
1 μM diazepam (Fig. 5C). The data were analyzed using Equation (1) where the value of L was modified to reflect
background activity due to direct gating by the modulator. Since direct gating by 1 μM alfaxalone or diazepam
could not be reliably measured (Po < 0.001), the level of activity (Po,background) in the presence of alfaxalone or
diazepam was calculated using Equation (1) and the K and c values for alfaxalone and diazepam determined in
the presence of GABA (Fig. 5B).
The estimates for KGABA and cGABA obtained in the presence of 1 μM alfaxalone were 39.5 ± 17.5 μM and
0.0046 ± 0.0016, and in the presence of 1 μM diazepam 40.8 ± 5.8 μM and 0.0047 ± 0.0005. These values are
ScIeNTIFIc REPOrtS | (2018) 8:10341 | DOI:10.1038/s41598-018-28754-7
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Figure 5. Activation and modulation of concatemeric α1β2γ2L GABAA receptors. (A) Direct activation of the
receptor by GABA, propofol (PRO), or alfaxalone (ALF). The ordinate shows the estimated open probability (Po).
The curves for GABA and propofol were generated by fitting Equation (1) to experimental data. Direct activation
by alfaxalone produced very small currents (<100 nA at 30 μM). The predicted activation curve for alfaxalone was
generated using KALF and cALF values determined in (B). (B) Potentiation of GABA-activated receptors by propofol,
alfaxalone, or diazepam (DZP). The solid curves were generated by fitting Equation (1) to the data. L was held at
(1 − Po,2 μM GABA)/Po,2 μM GABA. The dashed line shows the predicted propofol-potentiation curve using KPRO and cPRO
values from (A). (C) Activation by GABA in the presence of 1 μM diazepam, 1 μM alfaxalone or the combination
of diazepam + alfaxalone. The curves for single modulators were generated by fitting Equation (1) to the data. L
was held at at (1 − Po,1 μM ALF)/Po,1 μM ALF or at (1 − Po,1 μM DZP)/Po,1 μM DZP . The open probability for receptors activated
by 1 μM alfaxalone or 1 μM diazepam was calculated from the KALF and cALF, or KDZP and cDZP values estimated in
(B). The simulated curve for the combination of diazepam + alfaxalone was calculated using Equation (1) and the
KGABA and cGABA values from (A), and KALF, cALF, KDZP and cDZP values from (B). (D) Activation by GABA in the
presence of 10 μM propofol, 1 μM alfaxalone or the combination of propofol + alfaxalone. The curve for propofol
(green dashed line) is based on data from a previous report45. The data for alfaxalone are reproduced from panel C.
The simulated curve for the combination of propofol + alfaxalone was calculated using Equation (1) and the KGABA,
cGABA, KPRO and cPRO values from (A), and KALF and cALF values from (B). In (C) and (D), the black dotted lines
show the GABA concentration-response relationship in the absence of modulators (from A). In all panels the data
points show mean ± S.D. from at least five cells.

Agonist

Background agonist

L

K (μM)

c

GABA

None

9000

35.3 ± 6.6

0.0045 ± 0.0004

Propofol

None

9000

44.8 ± 8.9

0.04 ± 0.002

Alfaxalone

2 μM GABA

66 ± 36

2.9 ± 0.5

0.11 ± 0.006

Diazepam

2 μM GABA

37 ± 16

0.17 ± 0.02

0.18 ± 0.004

Table 1. Summary of activation properties. The K (equilibrium dissociation constant of the closed receptor)
and c (ratio of the equilibrium dissociation constant of the closed receptor to that of the open receptor) values
were estimated by fitting Equation (1) to the concentration-response data (Fig. 5). The number of binding sites
was held at 2 for GABA, 3 for propofol, 2 for alfaxalone, and 1 for diazepam (see Methods). The value for L was
held at 9000 in the absence of a background agonist or at the value calculated from estimated open probability
of the background agonist (2 μM GABA) as (1 − Po,background)/Po,background.
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remarkably similar to the KGABA and cGABA estimates obtained in experiments conducted in the absence of modulators (35.3 μM for KGABA and 0.0045 for cGABA) thereby indicating that the effects of alfaxalone and diazepam
on GABA-activated receptors can be accounted for by independent and additive energetic contributions to the
open-closed equilibrium. We attempted fitting the curves to a full co-agonist model18 with no constraints on K
and c for either agonist. However, the fits did not converge, possibly due to poorly defined responses at low GABA
concentrations.
Finally, we examined the effect of the combinations of 1 μM diazepam +1 μM alfaxalone and 10 μM propofol
+1 μM alfaxalone on the GABA concentration-response relationship. These drug combinations tested the energetic independence and additivity of the agonists in the three-drug mixtures of GABA + diazepam + alfaxalone
and GABA + propofol + alfaxalone. The predicted Po curves (Fig. 5C,D), generated assuming that each agonist
independently and energetically additively contributed to channel opening, are in good agreement with the
experimental data points.
Overall, the data indicate that in the agonist combinations of GABA ± diazepam ± alfaxalone and
GABA ± propofol ± alfaxalone, each drug acts independently and energetically additively to stabilize the open
state of the concatemeric α1β2γ2L GABAA receptor. In the framework of the state function of the co-agonist
model (Equation 1), each drug in these agonist combinations alters the value of L with no effect on the affinity
(K) or efficacy (c) of the others. We note that energetic additivity manifests as apparent synergy because, at least at
low drug concentrations, the response to the drug combination is greater than the sum of individual responses22.

Discussion

Propofol, diazepam and alfaxalone potentiate transmitter-elicited current responses from the GABAA receptor14–17. Additionally, propofol is an efficacious direct activator of the receptor20,21,23. The GABAergic activity
of these compounds underlies their sedative and anesthetic effects24–26. The goal of this study was to establish
whether coapplication of the neuroactive steroid alfaxalone modifies the actions of propofol and diazepam in
different assays aimed at measuring GABAergic inhibitory activity. Specifically, we determined the effects of combining alfaxalone with propofol or diazepam on sedation-like behavior in mice by analyzing time spent at rest
and loss-of-righting during an activity test conducted over the 30-min post-injection period. The doses of the
drugs were selected to elicit minimal effect when administered alone. The behavioral endpoints were correlated
with the effects of combining alfaxalone with propofol or diazepam on the decay time properties of sIPSCs from
hippocampal neurons, and on peak current responses from recombinant concatemeric synaptic-type α1β2γ2L
GABAA receptors.
We report that co-administration of alfaxalone with either propofol or diazepam in mice greatly amplifies
effects on sedation-like behavior. Intraperitoneal injections of the combinations of propofol + alfaxalone and
diazepam + alfaxalone resulted in significantly enhanced levels of time spent at rest, compared to mice exposed
to a single drug or saline-control treatments. Analysis of behavioral performance over the post-injection test
session showed that both combinatorial drug treatments involving alfaxalone produced fast-acting changes in
sedation-like behavior such that they each increased time at rest by the first 5-min time block compared to the
single drug treatment or saline control groups. Analyzing behavioral responses over the post-injection time also
revealed that the diazepam + alfaxalone treatment produced robust increases in rest times throughout the entire
30-min session relative to the single drug/saline groups, while the propofol + alfaxalone administration produced
a shorter period of discernible effects, which were limited to the first 20 min post-injection.
Diazepam is often used as an anxiolytic whereas sedation is an undesired side effect. The data, as evaluated by
the time at rest, show that co-administration of diazepam and alfaxalone increases the sedative effect of diazepam alone. Our study was not designed to test the anxiolytic effects of the drugs and drug combinations, and the
potential clinical usefulness of diazepam + alfaxalone remains to be determined in future studies.
Co-administration of propofol and alfaxalone resulted in loss-of-righting in 10/12 animals whereas none
of the animals administered either drug alone or saline experienced loss-of-righting. At the doses selected the
combination of diazepam + alfaxalone resulted in loss-of-righting in only 2/10 mice. The difference in the effects
of propofol vs. diazepam when administered in combination with alfaxalone in producing loss-of-righting may
be attributable to the differences in GABAA receptor subunit selectivity of the drugs, and the mediation of certain sedation-related behaviors by particular subtypes of the receptor. Benzodiazepines, such as diazepam, are
selective for GABAA receptors containing a γ subunit27 which are predominantly localized to synapses28. Propofol
and neuroactive steroids modulate all heteromeric GABAA receptor subtypes, including δ subunit-containing
extrasynaptic receptors, and are effective anesthetics. A low dose of alfaxalone can only enhance the actions of
diazepam at receptor subtypes that are modulated by benzodiazepines and can thus enhance diazepam’s anxiolytic/sedative effects. In contrast, alfaxalone can enhance the actions of propofol at all GABAA receptor subtypes
and thus enhances both its sedative and anesthetic effects.
The effects of combinations of alfaxalone with propofol on sIPSCs were supra-additive at several concentration combinations where propofol applied alone had no effect on τD but significantly enhanced the ability of
alfaxalone to modulate the decay time course. For diazepam + alfaxalone, the effects on τD were greater for the
combination than for either drug applied alone, however, each drug applied alone produced a significant effect.
In two-electrode voltage clamp recordings, we employed quantitative analysis based on the co-agonist concerted transition model18 to determine the binding and gating properties for GABA, propofol, alfaxalone, and
diazepam. The major finding is that the effects of the drugs can be accounted for by independent and additive changes in free energy. The functional effects of the combinations of GABA ± propofol ± alfaxalone and
GABA ± diazepam ± alfaxalone could be accurately predicted from the individual effects of the drugs on the
open-closed equilibrium assuming independent energetic contributions. We note that the observed energetic
additivity predicts that the drug combinations exhibit synergy in isobolographic analysis22.
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The effective concentrations of the GABAergic modulators were similar in neuronal and oocyte preparations.
A 2-3-fold prolongation (statistically significant) of the decay times of sIPSCs was observed in the presence of
300 nM alfaxalone, 1 μM propofol or 10–100 nM diazepam. Inhibitory synaptic events in hippocampal cultures
are mediated by GABAA receptors comprising α1, α2, β2, β3 and γ2 subunits29,30. In two-electrode voltage clamp
recordings on concatemeric α1β2γ2L receptors, these concentrations elicited an approximately 2-fold increase
in the peak response.
This study adds to the growing body of evidence demonstrating enhanced functional effects in electrophysiological and behavioral assays resulting from exposure to combinations of GABAergic modulators. Anesthetic
steroids potentiate the actions of the intravenous anesthetics propofol and etomidate in electrophysiological8 and behavioral assays9,31. Similarly, coapplication of neuroactive steroids enhances the anxiolytic effect
of the benzodiazepine triazolam32,33 and the anticonvulsant potency of diazepam against seizures induced by
pentylenetetrazol34.
In summary, our results show that the GABAergic effects of propofol and diazepam are enhanced in the
presence of alfaxalone. Quantitative analysis of electrophysiological responses from heterologously-expressed
receptors shows that the effects of drug combinations are accounted for by independent and additive energetic
effects of the modulators, which predict curvilinear isoboles of additivity that are typically associated with synergy. Examination of the properties of sIPSCs indicates that combination of alfaxalone with subthreshold concentrations of propofol elicits supra-additive effects on the decay times of sIPSCs. Behavioral tests in mice show that
the actions of propofol and diazepam are amplified in the presence of alfaxalone. These are potentially valuable
findings. In cases where the two drugs in a pair are linked to different off-target effects, the combinations of drugs
enable reduction of the dose of each drug and, while retaining an intended GABAergic output, may lower the
off-target side effects.

Methods

Behavioral assays. Behavioral assays were conducted on 7-week old male Swiss-Webster mice. The experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health. The protocol for use of mice was approved by the Animal Studies Committee of Washington
University in St. Louis (Approval Nos 20150065; 20150076).
A total of 85 mice purchased from Taconic (Hudson, NY) were acclimated to the new housing conditions for
at least 1 week prior to behavioral testing. All mice were housed in a 12/12-light/dark schedule with ad libitum
access to food and water. Initial experiments were conducted with alfaxalone, propofol, and diazepam to establish
doses that appeared to produce sedation based on the results of ambulatory activity (data not shown) and subsequent injections were performed using a presumed subsedative dose of each drug.
For experiments testing the combinatorial effects of alfaxalone and propofol, mice were injected intraperitoneally either with 20 Units of normal saline, 50 mg/kg propofol, 30 mg/kg alfaxalone, or both 50 mg/kg propofol and
30 mg/kg alfaxalone (n = 11–12 mice per group). Immediately following injection mice were placed individually
into translucent (47.6 × 25.4 × 20.6 cm) chambers and sedation-related behavior was quantified over a 30-min
period using computerized photobeam instrumentation and standard algorithms as previously described35,36.
The dependent variable for characterizing the sedative effects of drug treatments was time spent at rest, i.e., lack
of movement. This was defined by an absence of a change in the status of any floor-level, photocell pairs (either
newly cleared or blocked) along the x- and y-axes for at least a 2-s period. No baseline behavioral measures were
collected to minimize possible “floor effects” resulting from decreased motor activity accruing from habituation
to the testing environment, and thus help increase sensitivity for detecting sedative drug effects. The combinatorial effects of alfaxalone and diazepam were evaluated in the same manner except that mice were injected either
with normal saline, 4 mg/kg diazepam, 30 mg/kg alfaxalone, or both 4 mg/kg diazepam and 30 mg/kg alfaxalone
(n = 10 per group). The behavioral experiments were conducted within a 3-hr window to minimize changes in
baseline activity associated with circadian rhythm.
Animals were also scored for the loss of the righting reflex during activity testing, which was recorded when
a mouse spontaneously assumed a supine or prone position for greater than 30 seconds. This criterion avoided
spurious beam breaks that would have occurred from an experimenter placing a mouse on its back and recording
righting time when a mouse assumed an upright posture on all 4 limbs.
A repeated measures (rm) ANOVA model (SYSTAT 12, Systat Software, Inc., San Jose, CA), containing one
between-subjects variable (drug) and one within-subjects variable (time post-injection) was used to analyze the
time at rest data. Simple main effects tests were conducted after the rmANOVA to better understand the nature of
drug × time interactions. The Huynh-Feldt (H-F) adjustment of alpha levels was utilized for all within-subjects
effects containing more than two levels in order to help protect against violations of the sphericity/compound
symmetry assumptions underlying this ANOVA model. General normality of the data was assessed by conducting the Shapiro-Wilk test on the times at rest summed across the activity session for the propofol + alfaxalone
and diazepam + alfaxalone experiments. Results from this analysis did not reveal any significant departures from
normality. Bonferroni adjusted “p” values are presented and were computed by multiplying uncorrected “p” values by the number of comparisons that were conducted for a given analysis. Probability values of p = 0.0000 are
listed as p < 0.00005.
Hippocampal neurons, recordings and analysis of sIPSCs. Cultures of hippocampal neurons were
prepared from rat brains as described previously11,37. The experiments were conducted in accordance with the
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol for use of rats
was approved by the Animal Studies Committee of Washington University in St. Louis (Approval No. 2015019).
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Synaptic currents were recorded from neurons cultured for 9–14 days. Coverslips with cells were transferred
to a 60 mm dish containing 5 ml of bath solution. The bath solution contained (in mM): 140 NaCl, 5 KCl, 1
MgCl2, 2 CaCl2, 10 D-glucose, 10 HEPES (pH adjusted to 7.4 with NaOH). In some cases, 5 µM CNQX and 25 µM
DL-APV were added to bath to block glutamate receptor activity. In other cases, sIPSCs were distinguished from
sEPSCs by difference in decay properties38.
Drugs (propofol, diazepam, and/or alfaxalone) were added to the bath at the indicated concentrations at least
10 min before recording39. Each coverslip with neurons was exposed to a single drug or drug combination, to
avoid technical artifacts due to incomplete washout of these lipophilic compounds from the cells. Control recordings (not shown) indicate that the sIPSCs are abolished by bath exposure to bicuculline and picrotoxin.
The pipette solution contained (in mM): 140 CsCl, 4 NaCl, 4 MgCl2, 0.5 CaCl2, 5 EGTA, 10 HEPES (pH
adjusted to 7.4 with CsOH). Neurons were clamped at −70 mV. Pipette resistance was 4–5 MΩ. Series resistance
was compensated to 75–85% in most recordings. All experiments were done at room temperature.
Currents were amplified with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA), low-pass
filtered at 1 kHz and digitized with a Digidata 1322 A interface (Molecular Devices) at 5 kHz. The detection
and analysis of synaptic currents were conducted using pClamp 10 software (Molecular Devices) as described
previously11.
The decay time courses of sIPSCs were characterized by determining the 100-to-25% decay time. We used this
parameter rather than fitting the decay time course to sums of exponentials because of variability in the numbers
of exponentials required for adequate fit in the presence of high concentrations of steroid and propofol. The data
are expressed as mean ± S.D. (number of cells). The statistical analysis on decay times of sIPSCs was conducted
using ANOVA with Dunnett’s correction (Stata/IC 12.1, StataCorp, College Station, TX).

Expression of recombinant GABAA receptors and two-electrode voltage-clamp recordings from
Xenopus oocytes. Oocytes from Xenopus laevis (purchased from Xenopus 1, Dexter, MI) were used as the

expression system for recombinant GABAA receptors. Oocyte harvest and animal handling were carried out in
accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocol for use of frogs was approved by the Animal Studies Committee of Washington University in St. Louis
(Approval No. 20170071).
Electrophysiological recordings were conducted on rat GABAA receptors consisting of β2-α1-γ2L and β2-α1
concatemeric constructs, which have been shown to assemble as βαγβα (counterclockwise, top view)40. The
generation and functional characterization of the concatemeric receptors have been reported previously41. The
cDNAs in the pcDNA3 expression vector were linearized by digestion with Xba I (NEB Labs, Ipswich, MA).
The cRNAs were produced using mMessage mMachine (Ambion, Austin, TX). Oocytes were injected with a
total of 18 ng of cRNA in nuclease-free water (final volume 32 nl) and incubated in ND96 with supplements
(96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, and the supplements 2.5 mM Na pyruvate,
100 U/ml penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamycin; adjusted to pH 7.4 with NaOH) at 16 °C.
Electrophysiological recordings were conducted during the next 2–3 days.
Recordings were conducted using standard two-electrode voltage clamp. The oocytes were clamped at
−60 mV. The chamber (RC-1Z, Warner Instruments, Hamden, CT) was perfused with bath (ND96) or bath containing the drugs at approximately 7 ml/min. The current responses were amplified with an Axoclamp 900 A
amplifier (Molecular Devices, Sunnyvale, CA), filtered at 10 Hz, and digitized with a Digidata 1320 digitizer
(Molecular Devices) at a 50 Hz sampling rate. The traces were subsequently analyzed with Clampfit (Molecular
Devices) to determine the peak amplitude of the current response.
Receptor activity was analyzed in the co-agonist concerted transition model framework18,42. Raw current
amplitudes were converted to units of open probability (Po)43,44. To that end, the current responses from each
cell were compared to the reference response to 3 mM GABA + 50 μM propofol, that was considered to generate
a response with a Po indistinguishable from 121,45. For example, exposure to saturating GABA produced a peak
response that was 86 ± 8% (n = 9 cells) of the response to 3 mM GABA + 50 μM propofol. Accordingly, the maximal Po for GABA was estimated at 0.86 ± 0.08. This is similar to previous estimates of maximal Po for GABA in
the ternary αβγ receptor21,46,47. The level of activity in the absence of any GABAergic drugs (Po = 0.0001122) was
excluded in these calculations.
The binding and gating parameters were determined from fitting the pooled estimated Po data to the following
equation18,48:
Po =

1
1 + [drug]/K
1 + L ×  1 + [drug]/c K 



N

(1)

where K is the closed receptor equilibrium dissociation constant for the drug (GABA, propofol, alfaxalone, or
diazepam), c is a measure of receptor gating efficacy expressed as the ratio of the equilibrium dissociation constant of the open receptor to that of the closed receptor, and N is the number of binding sites for the agonist
(constrained to 2 for GABA49, 3 for propofol21, 2 for alfaxalone50, and 1 for diazepam51). Stabilization energy
provided by a drug was calculated as NRT × ln(c), where RT is the multiplication product of the gas constant and
thermodynamic temperature, and other terms are as described above.
The parameter L reflects unliganded or background activity from the receptor. In the absence of any
GABAergic agonists, it was constrained to 900021,22. In experiments where a low concentration of one GABAergic
drug, i.e., a background drug, was coapplied with a range of concentrations of a second GABAergic agonist, L
was calculated as (1 − Po,background)/Po,background, where Po,background is the open probability of the response to the
background drug. In a standard potentiation experiment, where several concentrations of a potentiator (propofol,
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alfaxalone or diazepam) were coapplied with a fixed low concentration of GABA, the response to GABA alone
comprised the background response. Since exposure to 1 μM alfaxalone or 1 μM diazepam did not produce robust
current responses, the Po,background for alfaxalone and diazepam were calculated using Equation (1) and the K and
c values estimated for each drug in the presence of low GABA. Curve-fitting was carried out using Origin v. 7.5
(OriginLab Corp., Northampton, MA).

Materials.

The salts used in buffers, alfaxalone, diazepam, CNQX and DL-APV used in electrophysiological
experiments were bought from Sigma-Aldrich (St. Louis, MO). Propofol was purchased from MP Biomedicals
(Solon, OH). Stock solution of alfaxalone was made in DMSO at 10 mM and stored at room temperature. Stock
solution of propofol was made in DMSO at 200 mM and stored at room temperature. For electrophysiological
recordings, stock solution of diazepam was made in ND96 at 30 μM and stored at −20 °C. Dilutions to lower
concentrations were made from that solution. The highest final concentration of DMSO was 0.3% (v/v). This
concentration of DMSO has been shown to be without effect on currents from recombinant α1β2γ2L GABAA
receptors or GABAA receptor-mediated synaptic currents52,53.
Pharmaceutical grade reagents were used in all behavioral experiments. Propofol (10 mg/ml, Hospira, Inc.,
San Jose, CA), alfaxalone (10 mg/ml, Jurox, Inc., Kansas City, MO), diazepam (5 mg/ml, Hospira, Inc.), combinations of either propofol and alfaxalone, or diazepam and alfaxalone, or sterile normal saline (20 Units) were
injected intraperitoneally using U-100 insulin syringes. Diazepam was diluted to 0.5 mg/ml with normal saline
prior to injection.

Data availability.

The datasets generated and/or analyzed during the current study are available from the
corresponding author on reasonable request.
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